Output/Publications
 
Papers published related to the Virgo consortium:


2005


  • van Baalen, C.A., Kwa, D., Verschuren, E.J., Reedijk, M.L., Boon, A.C., de Mutsert, G., Rimmelzwaan, G.J., Osterhaus, A.D., and Gruters, R.A. Fluorescent antigen-transfected target cell cytotoxic T lymphocyte assay for ex vivo detection of antigen-specific cell-mediated cytotoxicity. J. Infec. Dis. 2005. 192(7): 1183-90
  • Degen W.G., van Zuilekom H.I., Scholtes N.C., van Daal N., Schijns V.E. (2005). Potentiation of humoral immune responses to vaccine antigens by recombinant chicken IL-18 (rChIL-18). Vaccine 23, 4212-4218.
  • Degen W.G., Daal N., Rothwell L., Kaiser P., Schijns V.E. (2005). Th1/Th2 polarization by viral and helminth infection in birds. Vet Microbiol 105, 163-167.
  • Dekker L.J., Dalebout J.C.H., Siccama I., Jenster G., Sillevis Smitt P.A.E., Luider T.M. (2005) A new method to analyse matrix-assisted laser desorption/ionisation time-of-flight peptide profiling mass spectra. Rapid Communications in Mass Spectrometry 19, 1-6
  • Fouchier R., Kuiken T., Rimmelzwaan G., Osterhaus A. (2005). Global task force for influenza. Nature May 26;435(7041):419-20.
  • Huckriede, A., Bungener, L., Stegmann, T., Deamen, T., Medema, J., Palache, A.M. and Wilschut, J. (2005). The virosome concept for influenza vaccines. Vaccine 23 Suppl. 1, S26-S38
  • Nellist M., Burgers P.C., Van den Ouweland A.M.W., Halley D.J.J., Luider T.M. (2005) Phosphorylation and binding partner analysis of the TSC1-TSC2 complex. Biochem. Biophys. Res. Comm. 333, 818-826
  • van Rijt L.S., Jung S., Kleinjan A., Vos N., Willart M., Duez C., Hoogsteden H. C., Lambrecht B.N. (2005). In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J Exp Med 201, 981-991.
  • van Rijt L.S., van Kessel C.H., Boogaard I., Lambrecht B.N. (2005). Respiratory viral infections and asthma pathogenesis: a critical role for dendritic cells? J Clin Virol 34, 161-169.
  • van Rijt L.S., Lambrecht B.N. (2005) Dendritic cells in asthma: a function beyond sensitization Clin Exp Allergy vol 35, issue 39 p1125-34
  • Simon J.H., Claassen E., Correa C.E., Osterhaus A.D. (2005) Managing severe acute respiratory syndrome (SARS) intellectual property rights: the possible role of patent pooling. Bull. World Health Organ. Sep;83(9):707-10.
  • De Wit E., Munster V.J., Spronken M.I., Bestebroer T.M., Baas C., Beyer W.E., Rimmelzwaan G.F., Osterhaus A.D., Fouchier R.A. (2005) Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J Virol.  Oct;79(19):12401-7.


2006


  • Boon, A.C., G. de Mutsert, R.A. Fouchier, A.D. Osterhaus, and G.F. Rimmelzwaan. (2006). The hypervariable immunodominant NP418-426 epitope from the influenza A virus nucleoprotein is recognized by cytotoxic T lymphocytes with high functional avidity. J Virol 80:6024-6032.
  • de Jonge, J., P. Schoen, W. ter Veer, T. Stegmann, J. Wilschut, and A. Huckriede. (2006). Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes. Biochim Biophys Acta 1758:527-536.
  • de Jonge, J., M. Holtrop, J. Wilschut, and A. Huckriede. (2006). Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther 13:400-411.
  • de Waal, L., Y. Suzer, L.S. Wyatt, K. Sintnicolaas, G. Sutter, B. Moss, A.D. Osterhaus, and R.L. de Swart. (2006). T cell responses to respiratory syncytial virus fusion and attachment proteins in human peripheral blood mononuclear cells. Viral Immunol 19:669-678.
  • Degen, W.G., J. Smith, B. Simmelink, E.J. Glass, D.W. Burt, and V.E. Schijns. (2006). Molecular immunophenotyping of lungs and spleens in naive and vaccinated chickens early after pulmonary avian influenza A (H9N2) virus infection. Vaccine 24:6096-6109.
  • Dutilh, B.E., M.A. Huynen, and B. Snel. (2006). A global definition of expression context is conserved between orthologs, but does not correlate with sequence conservation. BMC Genomics 7:10.
  • Haagmans, B.L., and A.D. Osterhaus. (2006). Coronaviruses and their therapy. Antiviral Res 71:397-403.
  • Hammad H, Lambrecht BN. (2006). Recent progress in the biology of airway dendritic cells and implications for understanding the regulation of asthmatic inflammation. J Allergy Clin Immunol . 118:331-336.
  • Holvast, A., A. Huckriede, J. Wilschut, G. Horst, J.J. De Vries, C.A. Benne, C.G. Kallenberg, and M. Bijl. (2006). Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 65:913-918.
  • Hulsen, T., M.A. Huynen, J. de Vlieg, and P.M. Groenen. (2006). Benchmarking ortholog identification methods using functional genomics data. Genome Biol 7:R31.
  • Lambrecht, B.N., and L.S. van Rijt. (2006). Infections and asthma pathogenesis: a critical role for dendritic cells? Novartis Found Symp 279:187-200; discussion 200-185, 216-189.
  • Lambrecht, B.N. (2006). Alveolar macrophage in the driver's seat. Immunity 24:366-368.
  • Oti, M., B. Snel, M.A. Huynen, and H.G. Brunner. (2006). Predicting disease genes using protein-protein interactions. J Med Genet 43:691-698.
  • Postma, M.J. Baltussen, R.P.M., Palache, A.M. and Wilschut, J.C. (2006). Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Exp. Rev. Pharmacoeconomics Outcomes Res. 6: 215-227.
  • Smith, J., D. Speed, P.M. Hocking, R.T. Talbot, W.G. Degen, V.E. Schijns, E.J. Glass, and D.W. Burt. (2006). Development of a chicken 5 K microarray targeted towards immune function. BMC Genomics 7:49.
  • Staal, F.J., G. Cario, G. Cazzaniga, T. Haferlach, M. Heuser, W.K. Hofmann, K. Mills, M. Schrappe, M. Stanulla, L.U. Wingen, J.J. van Dongen, and B. Schlegelberger. (2006). Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia 20:1385-1392.
  • Titulaer, M.K., I. Siccama, L.J. Dekker, A.L. van Rijswijk, R.M. Heeren, P.A. Sillevis Smitt, and T.M. Luider. (2006). A database application for pre-processing, storage and comparison of mass spectra derived from patients and controls. BMC Bioinformatics 7:403.
  • Ulbrandt, N.D., H. Ji, N.K. Patel, J.M. Riggs, Y.A. Brewah, S. Ready, N.E. Donacki, K. Folliot, A.S. Barnes, K. Senthil, S. Wilson, M. Chen, L. Clarke, M. MacPhail, J. Li, R.M. Woods, K. Coelingh, J.L. Reed, M.P. McCarthy, D.S. Pfarr, A.D. Osterhaus, R.A. Fouchier, P.A. Kiener, and J.A. Suzich. (2006). Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol 80:7799-7806.
  • van Kampen, J.J., P.C. Burgers, R. de Groot, and T.M. Luider. (2006). Qualitative and quantitative analysis of pharmaceutical compounds by MALDI-TOF mass spectrometry. Anal Chem 78:5403-5411.
  • Verhaak, R.G., F.J. Staal, P.J. Valk, B. Lowenberg, M.J. Reinders, and D. de Ridder. (2006). The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies. BMC Bioinformatics 7:105.
  • Wallensten, A., V.J. Munster, M. Karlsson, A. Lundkvist, M. Brytting, M. Stervander, A.D. Osterhaus, R.A. Fouchier, and B. Olsen. (2006). High prevalence of influenza A virus in ducks caught during spring migration through Sweden. Vaccine 24:6734-6735.
  • Warris, A., and R. de Groot. (2006). Human metapneumovirus: an important cause of acute respiratory illness. Adv Exp Med Biol 582:251-264.
  • (2006). Misconceptions concerning influenza: an overview and clear answers. Vaccine 24:6779-6782.
  • Rimmelzwaan, G.F., J.C. de Jong, G.A. Donker, A. Meijer, R.A. Fouchier, and A.D. Osterhaus. (2006). [The 2005-2006 influenza season in the Netherlands and the vaccine composition for the 2006-2007 season] Het influenzaseizoen 2005 /2006 in Nederland en de vaccinsamenstelling voor het seizoen 2006/'07. Ned Tijdschr Geneeskd 150:2209-2214.
  • de Lang, A., A.D. Osterhaus, and B.L. Haagmans. (2006). Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology 353:474-481.
  • Berkhoff, E.G., E. de Wit, M.M. Geelhoed-Mieras, A.C. Boon, J. Symons, R.A. Fouchier, A.D. Osterhaus, and G.F. Rimmelzwaan. (2006). Fitness costs limit escape from cytotoxic T lymphocytes by influenza A viruses. Vaccine 24:6594-6596.
  • de Wit, E., M.I. Spronken, G.F. Rimmelzwaan, A.D. Osterhaus, and R.A. Fouchier. (2006). Evidence for specific packaging of the influenza A virus genome from conditionally defective virus particles lacking a polymerase gene. Vaccine 24:6647-6650.
  • Hampson, A.W., A.D. Osterhaus, Y. Pervikov, and M.P. Kieny. (2006). Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005. Vaccine 24:4897-4900.
  • Ducatez, M.F., C.M. Olinger, A.A. Owoade, S. De Landtsheer, W. Ammerlaan, H.G. Niesters, A.D. Osterhaus, R.A. Fouchier, and C.P. Muller. (2006). Avian flu: multiple introductions of H5N1 in Nigeria. Nature 442:37.
  • Olsen, B., V.J. Munster, A. Wallensten, J. Waldenstrom, A.D. Osterhaus, and R.A. Fouchier. (2006). Global patterns of influenza a virus in wild birds. Science 312:384-388.
  • van Riel, D., V.J. Munster, E. de Wit, G.F. Rimmelzwaan, R.A. Fouchier, A.D. Osterhaus, and T. Kuiken. (2006). H5N1 Virus Attachment to Lower Respiratory Tract. Science 312:399.


 



2007


  • Aerts, J. G., Amelink A., van der Leest C., Hegmans J. P., Hemmes A., den Hamer B., Sterenborg H. C., Hoogsteden H. C. and Lambrecht B. N. (2007) HIF1a expression in bronchial biopsies correlates with tumor microvascular saturation determined using optical spectroscopy. Lung Cancer 57, 317-21.

  • Amidi, M., S.G. Romeijn, J.C. Verhoef, H.E. Junginger, L. Bungener, A. Huckriede, D.J. Crommelin, and W. Jiskoot. (2007). N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine 25:144-153.

  • Amorij J. P., Meulenaar J., Hinrichs W. L., Stegmann T., Huckriede A., Coenen F. and Frijlink H. W. (2007a) Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 25, 6447-57.

  • Amorij J. P., Saluja V., Petersen A. H., Hinrichs W. L., Huckriede A. and Frijlink H. W. (2007b) Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine 25, 8707-17.

  • Amorij J. P., Westra T. A., Hinrichs W. L., Huckriede A. and Frijlink H. W. (2007c) Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model. Vaccine 26, 67-76.
  • Berkhoff, E.G., M.M. Geelhoed-Mieras, R.A. Fouchier, A.D. Osterhaus, and G.F. Rimmelzwaan. (2007a). Assessment of the extent of variation in influenza A virus cytotoxic T-lymphocyte epitopes by using virus-specific CD8+ T-cell clones. J Gen Virol 88:530-535.
  • Berkhoff E. G., Geelhoed-Mieras M. M., Jonges M., Smith D. J., Fouchier R. A., Osterhaus A. D. and Rimmelzwaan G. F. (2007b) An amino acid substitution in the influenza A virus hemagglutinin associated with escape from recognition by human virus-specific CD4+ T-cells. Virus Res 126, 282-7.
  • Berkhoff, E.G., M.M. Geelhoed-Mieras, E.J. Verschuren, C.A. van Baalen, R.A. Gruters, R.A. Fouchier, A.D. Osterhaus, and G.F. Rimmelzwaan. (2007c). The loss of immunodominant epitopes affects interferon-gamma production and lytic activity of the human influenza virus-specific cytotoxic T lymphocyte response in vitro. Clin Exp Immunol 148:296-306.
  • Datson, N.A., M.C. Morsink, S. Atanasova, V.W. Armstrong, H. Zischler, C. Schlumbohm, B.E. Dutilh, M.A. Huynen, B. Waegele, A. Ruepp, E.R. de Kloet, and E. Fuchs. (2007). Development of the first marmoset-specific DNA microarray (EUMAMA): a new genetic tool for large-scale expression profiling in a non-human primate. BMC Genomics 8:190.

  • de Graaf M., Herfst S., Schrauwen E. J., van den Hoogen B. G., Osterhaus A. D. and Fouchier R. A. (2007) An improved plaque reduction virus neutralization assay for human metapneumovirus. J Virol Methods 143, 169-74.

  • de Jong J. C., Rimmelzwaan G. F., Donker G. A., Meijer A., Fouchier R. A. and Osterhaus A. D. (2007a) [The 2006/'07 influenza season in the Netherlands and the vaccine composition for the 2007/'08 season]

    Het influenzaseizoen 2006/'07 in Nederland en de vaccinsamenstelling voor het seizoen 2007/'08. Ned Tijdschr Geneeskd 151, 2158-65.

  • de Jong, J.C., D.J. Smith, A.S. Lapedes, I. Donatelli, L. Campitelli, G. Barigazzi, K. Van Reeth, T.C. Jones, G.F. Rimmelzwaan, A.D. Osterhaus, and R.A. Fouchier. (2007). Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe. J Virol 81:4315-4322.
  • de Jonge, J., J.P. Amorij, W.L. Hinrichs, J. Wilschut, A. Huckriede, and H.W. Frijlink. (2007). Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. Eur J Pharm Sci 32:33-44.
  • de Jonge, J., J.M. Leenhouts, M. Holtrop, P. Schoen, P. Scherrer, P.R. Cullis, J. Wilschut, and A. Huckriede. (2007). Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. Biochem J 405:41-49.

  • de Lang A., Baas T., Teal T., Leijten L. M., Rain B., Osterhaus A. D., Haagmans B. L. and Katze M. G. (2007) Functional genomics highlights differential induction of antiviral pathways in the lungs of SARS-CoV-infected macaques. PLoS Pathog 3, e112.

  • de Swart, R.L., C. LiCalsi, A.V. Quirk, G. van Amerongen, V. Nodelman, R. Alcock, S. Yuksel, G.H. Ward, J.G. Hardy, H. Vos, C.L. Witham, C.I. Grainger, T. Kuiken, B.J. Greenspan, T.G. Gard, and A.D. Osterhaus. (2007). Measles vaccination of macaques by dry powder inhalation. Vaccine 25:1183-1190.
  • de Swart, R.L., M. Ludlow, L. de Witte, Y. Yanagi, G. van Amerongen, S. McQuaid, S. Yuksel, T.B. Geijtenbeek, W.P. Duprex, and A.D. Osterhaus. 2007. Predominant Infection of CD150(+) Lymphocytes and Dendritic Cells during Measles Virus Infection of Macaques. PLoS Pathog 3:e178.
  • de Swart, R.L., B.G. van den Hoogen, T. Kuiken, S. Herfst, G. van Amerongen, S. Yuksel, L. Sprong and A.D. Osterhaus. 2007. Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine.
  • de Wit, E., T.M. Bestebroer, M.I. Spronken, G.F. Rimmelzwaan, A.D. Osterhaus, and R.A. Fouchier. (2007). Rapid sequencing of the non-coding regions of influenza A virus. J Virol Methods 139:85-89.
  • de Wit, E., M.I. Spronken, G. Vervaet, G.F. Rimmelzwaan, A.D. Osterhaus, and R.A. Fouchier. (2007). A reverse-genetics system for Influenza A virus using T7 RNA polymerase. J Gen Virol 88:1281-1287.
  • Dekker, L.J., P.C. Burgers, C. Guzel, and T.M. Luider. (2007). FTMS and TOF/TOF mass spectrometry in concert: identifying peptides with high reliability using matrix prespotted MALDI target plates. J Chromatogr B Analyt Technol Biomed Life Sci 847:62-64.

  • Ducatez M. F., Olinger C. M., Owoade A. A., Tarnagda Z., Tahita M. C., Sow A., De Landtsheer S., Ammerlaan W., Ouedraogo J. B., Osterhaus A. D., Fouchier R. A. and Muller C. P. (2007a) Molecular and antigenic evolution and geographical spread of H5N1 highly pathogenic avian influenza viruses in western Africa. J Gen Virol 88, 2297-306.

  • Ducatez M. F., Tarnagda Z., Tahita M. C., Sow A., de Landtsheer S., Londt B. Z., Brown I. H., Osterhaus D. M., Fouchier R. A., Ouedraogo J. B. and Muller C. P. (2007b) Genetic characterization of HPAI (H5N1) viruses from poultry and wild vultures, Burkina Faso. Emerg Infect Dis 13, 611-3.

  • El Mubarak, H.S., S. Yuksel, G. van Amerongen, P.G. Mulder, M.M. Mukhtar, A.D. Osterhaus, and R.L. de Swart. (2007). Infection of cynomolgus macaques (Macaca fascicularis) and rhesus macaques (Macaca mulatta) with different wild-type measles viruses. J Gen Virol 88:2028-2034.

  • Gutierrez L., Nikolic T., van Dijk T. B., Hammad H., Vos N., Willart M., Grosveld F., Philipsen S. and Lambrecht B. N. (2007) Gata1 regulates dendritic-cell development and survival. Blood 110, 1933-41.

  • Hammad H., Kool M., Soullie T., Narumiya S., Trottein F., Hoogsteden H. C. and Lambrecht B. N. (2007) Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells. J Exp Med 204, 357-67.

  • Hammad H. and Lambrecht B. N. (2007) Lung dendritic cell migration. Adv Immunol 93, 265-78.

  • Hamming, I., M.E. Cooper, B.L. Haagmans, N.M. Hooper, R. Korstanje, A.D. Osterhaus, W. Timens, A.J. Turner, G. Navis, and H. van Goor. (2007). The emerging role of ACE2 in physiology and disease. J Pathol 212:1-11.

  • Herfst S., de Graaf M., Schrauwen E. J., Ulbrandt N. D., Barnes A. S., Senthil K., Osterhaus A. D., Fouchier R. A. and van den Hoogen B. G. (2007) Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains. J Gen Virol 88, 2702-9.

  • Hoebeke, I., M. De Smedt, F. Stolz, K. Pike-Overzet, F.J. Staal, J. Plum, and G. Leclercq. (2007). T-, B- and NK-lymphoid, but not myeloid cells arise from human CD34(+)CD38(-)CD7(+) common lymphoid progenitors expressing lymphoid-specific genes. Leukemia 21:311-319.
  • Holvast, B., A. Huckriede, C.G. Kallenberg, and M. Bijl. (2007). Influenza vaccination in systemic lupus erythematosus: safe and protective? Autoimmun Rev 6:300-305.
  • Huckriede, A., J. De Jonge, M. Holtrop, and J. Wilschut. (2007). Cellular delivery of siRNA mediated by fusion-active virosomes. J Liposome Res 17:39-47.

  • Idzko M., Hammad H., van Nimwegen M., Kool M., Vos N., Hoogsteden H. C. and Lambrecht B. N. (2007a) Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest 117, 464-72.

  • Idzko M., Hammad H., van Nimwegen M., Kool M., Willart M. A., Muskens F., Hoogsteden H. C., Luttmann W., Ferrari D., Di Virgilio F., Virchow J. C., Jr. and Lambrecht B. N. (2007b) Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 13, 913-9.
  • Jansen, T., M.P. Hofmans, M.J. Theelen, F.G. Manders, and V.E. Schijns. (2007). Dose and timing requirements for immunogenicity of viral poultry vaccine antigen: investigations of emulsion-based depot function. Avian Pathol 36:361-365.

  • Kool M. and Lambrecht B. N. (2007) Dendritic cells in asthma and COPD: opportunities for drug development. Curr Opin Immunol 19, 701-10.

  • Kreijtz, J.H., R. Bodewes, G. van Amerongen, T. Kuiken, R.A. Fouchier, A.D. Osterhaus, and G.F. Rimmelzwaan. (2007). Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25:612-620.
  • Kreijtz, J.H., Y. Suezer, G. van Amerongen, G. de Mutsert, B.S. Schnierle, J.M. Wood, T. Kuiken, R.A. Fouchier, J. Lower, A.D. Osterhaus, G. Sutter, and G.F. Rimmelzwaan. (2007). Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 195:1598-1606.

  • Lambrecht B. N. (2007) Lung dendritic cells: from basic physiology to clinical applications. Acta Clin Belg 62, 330-4.

  • Lambrecht B. N. and van den Toorn L. M. (2007) The pressure mounts on lung dendritic cells. Eur Respir J 29, 435-7.

  • Munster V. J., de Wit E., van Riel D., Beyer W. E., Rimmelzwaan G. F., Osterhaus A. D., Kuiken T. and Fouchier R. A. (2007) The molecular basis of the pathogenicity of the Dutch highly pathogenic human influenza A H7N7 viruses. J Infect Dis 196, 258-65.

  • Mustafa, D.A., P.C. Burgers, L.J. Dekker, H. Charif, M.K. Titulaer, P.A. Smitt, T.M. Luider, and J.M. Kros. (2007). Identification of glioma neovascularization-related proteins by using MALDI-FTMS and nano-LC fractionation to microdissected tumor vessels. Mol Cell Proteomics 6:1147-1157.
  • Osterhaus, A.D. (2007). Pre- or post-pandemic influenza vaccine? Vaccine 25:4983-4984.

  • Osterhaus A. D. and Vanlangendonck C. (2007) Chapter III. The second European Influenza Conference--lessons learnt and actions to take. The urgent need for a European influenza task force. Vaccine 25, 2155-60.

  • Philippa, J., C. Baas, W. Beyer, T. Bestebroer, R. Fouchier, D. Smith, W. Schaftenaar, and A. Osterhaus. (2007). Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adjuvanted inactivated H5N2 vaccine. Vaccine 25:3800-3808.
  • Postma, M.J., A. Novak, H.W. Scheijbeler, M. Gyldmark, M.L. van Genugten, and J.C. Wilschut. (2007). Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands. Pharmacoeconomics 25:497-509.

  • Rimmelzwaan G. F., Fouchier R. A. and Osterhaus A. D. (2007a) Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 18, 529-36.

  • Rimmelzwaan G. F., Nieuwkoop N. J., de Mutsert G., Boon A. C., Kuiken T., Fouchier R. A. and Osterhaus A. D. (2007b) Attachment of infectious influenza A viruses of various subtypes to live mammalian and avian cells as measured by flow cytometry. Virus Res 129, 175-81.

  • Schijns, V.E., and W.G. Degen. (2007). Vaccine immunopotentiators of the future. Clin Pharmacol Ther 82:750-755.

  • Smits H. H., Hammad H., van Nimwegen M., Soullie T., Willart M. A., Lievers E., Kadouch J., Kool M., Kos-van Oosterhoud J., Deelder A. M., Lambrecht B. N. and Yazdanbakhsh M. (2007) Protective effect of Schistosoma mansoni infection on allergic airway inflammation depends on the intensity and chronicity of infection. J Allergy Clin Immunol 120, 932-40.

  • van den Hoogen, B.G., S. Herfst, M. de Graaf, L. Sprong, R. van Lavieren, G. van Amerongen, S. Yuksel, R.A. Fouchier, A.D. Osterhaus, and R.L. de Swart. (2007). Experimental infection of macaques with human metapneumovirus induces transient protective immunity. J Gen Virol 88:1251-1259.
  • van Kampen, J.J., E.J. Verschuren, P.C. Burgers, T.M. Luider, R. de Groot, A.D. Osterhaus, and R.A. Gruters. (2007). Validation of an HIV-1 inactivation protocol that is compatible with intracellular drug analysis by mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 847:38-44. 

  • van Noort V., Snel B. and Huynen M. A. (2007) Exploration of the omics evidence landscape: adding qualitative labels to predicted protein-protein interactions. Genome Biol 8, R197.

  • van Riel D., Munster V. J., de Wit E., Rimmelzwaan G. F., Fouchier R. A., Osterhaus A. D. and Kuiken T. (2007) Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am J Pathol 171, 1215-23.
  • Wallensten A., Munster V. J., Latorre-Margalef N., Brytting M., Elmberg J., Fouchier R. A., Fransson T., Haemig P. D., Karlsson M., Lundkvist A., Osterhaus A. D., Stervander M., Waldenstrom J. and Bjorn O. (2007) Surveillance of influenza A virus in migratory waterfowl in northern Europe. Emerg Infect Dis 13, 404-11.

  • Wilschut J., de Jonge J., Huckriede A., Amorij J. P., Hinrichs W. L. and Frijlink H. W. (2007) Preservation of influenza virosome structure and function during freeze-drying and storage. J Liposome Res 17, 173-82.



2008


  • Assink MD, Kiewiet JP, Rozenbaum MH, et al. Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential implications for extended influenza vaccination. Vaccine 2009;27(7):1119-26. [IF 3.3]
  • Bodewes R, Geelhoed-Mieras MM, Heldens JG, et al. The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro. Vaccine 2009;27(49):6833-9. [IF 3.3]
  • Bodewes R, Kreijtz JH, Baas C, et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PloS one 2009;4(5):e5538. [IF 5.7]
  • de Goede AL, Boers PH, Dekker LJ, Osterhaus AD, Gruters RA, Rimmelzwaan GF. Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag. Vaccine 2009;27(42):5735-9. [IF 3.3]
  • de Graaf M, Schrauwen EJ, Herfst S, van Amerongen G, Osterhaus AD, Fouchier RA. Fusion protein is the main determinant of metapneumovirus host tropism. The Journal of general virology 2009;90(Pt 6):1408-16. [IF 3.1]
  • de Lang A, Baas T, Smits SL, Katze MG, Osterhaus AD, Haagmans BL. Unraveling the complexities of the interferon response during SARS-CoV infection. Future virology 2009;4(1):71-8. [IF 0.4]
  • de Swart RL. Measles studies in the macaque model. Current topics in microbiology and immunology 2009;330:55-72. [IF 5.1]
  • de Swart RL, Yuksel S, Langerijs CN, Muller CP, Osterhaus AD. Depletion of measles virus glycoprotein-specific antibodies from human sera reveals genotype-specific neutralizing antibodies. The Journal of general virology 2009;90(Pt 12):2982-9. [IF 3.1]
  • de Vries JJ, Bungener L, Ter Veer W, et al. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. Vaccine 2009;27(6):947-55. [IF 3.3]
  • Dekker LJ, van Kampen JJ, Reedijk ML, et al. A mass spectrometry based imaging method developed for the intracellular detection of HIV protease inhibitors. Rapid Commun Mass Spectrom 2009;23(8):1183-8. [IF 2.8]
  • Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science (New York, NY 2009;325(5937):197-201. [IF28.1]
  • Giuseppe Del Giudice, Koert J. Stittelaar, Geert van Amerongen, James Simon, Albert D. M. E. Osterhaus, Klaus Stöhr, Rino Rappuoli, Seasonal Influenza Vaccine Provides Priming For A/H1N1 Immunization, www.ScienceTranslationalMedicine.org 23, December 2009, Vol 1 Issue 12 12re1 [no IF]
  • GeurtsvanKessel CH, Bergen IM, Muskens F, et al. Both conventional and interferon killer dendritic cells have antigen-presenting capacity during influenza virus infection. PloS one 2009;4(9):e7187. [IF 5.7]
  • GeurtsvanKessel CH, Willart MA, Bergen IM, et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. The Journal of experimental medicine 2009;206(11):2339-49. [IF 15.6]
  • Haagmans BL, Andeweg AC, Osterhaus AD. The application of genomics to emerging zoonotic viral diseases. PLoS pathogens 2009;5(10):e1000557. [IF 9.1]
  • Hahne S, Donker T, Meijer A, et al. Epidemiology and control of influenza A(H1N1)v in the Netherlands: the first 115 cases. Euro Surveill 2009;14(27). [IF will be determined in 2011]
  • Holvast A, Stegeman CA, Benne CA, et al. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Annals of the rheumatic diseases 2009;68(6):873-8. [IF 7.1]
  • Holvast A, van Assen S, de Haan A, et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis and rheumatism 2009;60(8):2438-47. [IF 6.8]
  • Holvast A, van Assen S, de Haan A, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology (Oxford, England) 2009;48(10):1294-9. [IF 4.1]
  • Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD. Vaccine-induced enhancement of viral infections. Vaccine 2009;27(4):505-12. [IF 3.3]
  • Koopmans MP, Meijer A, van der Lubben MI, et al. [Combating the new influenza A (H1N1) virus. I. Overview of the relevant virological aspects]. Nederlands tijdschrift voor geneeskunde 2009;153:A770. [no IF]
  • Kreijtz JH, Bodewes R, van den Brand JM, et al. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 2009;27(36):4983-9. [IF 3.3]
  • Kreijtz JH, Osterhaus AD, Rimmelzwaan GF. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Human vaccines 2009;5(3):126-35. [IF 1.5]
  • Kreijtz JH, Suezer Y, de Mutsert G, et al. MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PloS one 2009;4(11):e7790. [IF 5.7]
  • Kreijtz JH, Suezer Y, de Mutsert G, et al. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 2009;27(45):6296-9. [IF 3.3]
  • Kreijtz JH, Suezer Y, de Mutsert G, et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. The Journal of infectious diseases 2009;199(3):405-13. [IF 5.7]
  • Latorre-Margalef N, Gunnarsson G, Munster VJ, et al. Effects of influenza A virus infection on migrating mallard ducks. Proceedings 2009;276(1659):1029-36. [IF 4.2]
  • Meijer A, Beerens A, Claas E, et al. Preparing the outbreak assistance laboratory network in the Netherlands for the detection of the influenza virus A(H1N1) variant. J Clin Virol 2009;45(3):179-84. [IF 3.3]
  • Munster VJ, Baas C, Lexmond P, et al. Practical considerations for high-throughput influenza A virus surveillance studies of wild birds by use of molecular diagnostic tests. Journal of clinical microbiology 2009;47(3):666-73. [IF 3.9]
  • Munster VJ, de Wit E, van den Brand JM, et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science (New York, NY 2009;325(5939):481-3. [IF 28.1]
  • Nauta JJ, Beyer WE, Osterhaus AD. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals 2009;37(4):216-21. [IF 1.1]
  • Osterhaus AD, Vanlangendonck C. Stakeholder dialogue, broadening of support and use of communication: an integrated and integral part of influenza preparedness. Vaccine 2009;27(45):6390-1. [IF 3.3]
  • Pike-Overzet K, de Ridder D, Schonewille T, Staal FJ. DNA microarray studies of hematopoietic subpopulations. Methods in molecular biology (Clifton, NJ 2009;506:403-21. [IF unknown]
  • Rappuoli R, Del Giudice G, Nabel GJ, et al. Public health. Rethinking influenza. Science (New York, NY 2009;326(5949):50. [IF 28.1]
  • Reemers SS, Groot Koerkamp MJ, Holstege FC, van Eden W, Vervelde L. Cellular host transcriptional responses to influenza A virus in chicken tracheal organ cultures differ from responses in in vivo infected trachea. Veterinary immunology and immunopathology 2009;132(2-4):91-100. [IF 1.9]
  • Reemers SS, van Haarlem DA, Groot Koerkamp MJ, Vervelde L. Differential gene-expression and host-response profiles against avian influenza virus within the chicken lung due to anatomy and airflow. The Journal of general virology 2009;90(Pt 9):2134-46. [IF 3.1]
  • Rimmelzwaan GF, Kreijtz JH, Bodewes R, Fouchier RA, Osterhaus AD. Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 2009;27(45):6363-5. [IF 3.3]
  • Rockx B, Baas T, Zornetzer GA, et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. Journal of virology 2009;83(14):7062-74. [IF 5.3]
  • Scharpe J, Peetermans WE, Vanwalleghem J, et al. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis 2009;54(1):77-85. [IF 4.8]
  • van Haarlem DA, van Kooten PJ, Rothwell L, Kaiser P, Vervelde L. Characterisation and expression analysis of the chicken interleukin-7 receptor alpha chain. Developmental and comparative immunology 2009;33(9):1018-26. [IF 2.8]
  • van Riel D, van den Brand JM, Munster VJ, et al. Pathology and virus distribution in chickens naturally infected with highly pathogenic avian influenza A virus (H7N7) During the 2003 outbreak in The Netherlands. Veterinary pathology 2009;46(5):971-6. [IF 1.4]
  • Wilschut J. Influenza vaccines: the virosome concept. Immunology letters 2009;122(2):118-21. [IF 2.9]
  • Zijtregtop EA, Wilschut J, Koelma N, et al. Which factors are important in adults' uptake of a (pre)pandemic influenza vaccine? Vaccine 2009;28(1):207-27. [IF 3.3]


2009


  • Assink MD, Kiewiet JP, Rozenbaum MH, et al. Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential implications for extended influenza vaccination. Vaccine 2009;27(7):1119-26. [IF 3.3]
  • Bodewes R, Geelhoed-Mieras MM, Heldens JG, et al. The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro. Vaccine 2009;27(49):6833-9. [IF 3.3]
  • Bodewes R, Kreijtz JH, Baas C, et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PloS one 2009;4(5):e5538. [IF 5.7]
  • de Goede AL, Boers PH, Dekker LJ, Osterhaus AD, Gruters RA, Rimmelzwaan GF. Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag. Vaccine 2009;27(42):5735-9. [IF 3.3]
  • de Graaf M, Schrauwen EJ, Herfst S, van Amerongen G, Osterhaus AD, Fouchier RA. Fusion protein is the main determinant of metapneumovirus host tropism. The Journal of general virology 2009;90(Pt 6):1408-16. [IF 3.1]
  • de Lang A, Baas T, Smits SL, Katze MG, Osterhaus AD, Haagmans BL. Unraveling the complexities of the interferon response during SARS-CoV infection. Future virology 2009;4(1):71-8. [IF 0.4]
  • de Swart RL. Measles studies in the macaque model. Current topics in microbiology and immunology 2009;330:55-72. [IF 5.1]
  • de Swart RL, Yuksel S, Langerijs CN, Muller CP, Osterhaus AD. Depletion of measles virus glycoprotein-specific antibodies from human sera reveals genotype-specific neutralizing antibodies. The Journal of general virology 2009;90(Pt 12):2982-9. [IF 3.1]
  • de Vries JJ, Bungener L, Ter Veer W, et al. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. Vaccine 2009;27(6):947-55. [IF 3.3]
  • Dekker LJ, van Kampen JJ, Reedijk ML, et al. A mass spectrometry based imaging method developed for the intracellular detection of HIV protease inhibitors. Rapid Commun Mass Spectrom 2009;23(8):1183-8. [IF 2.8]
  • Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science (New York, NY 2009;325(5937):197-201. [IF28.1]
  • Giuseppe Del Giudice, Koert J. Stittelaar, Geert van Amerongen, James Simon, Albert D. M. E. Osterhaus, Klaus Stöhr, Rino Rappuoli, Seasonal Influenza Vaccine Provides Priming For A/H1N1 Immunization, www.ScienceTranslationalMedicine.org 23, December 2009, Vol 1 Issue 12 12re1 [no IF]
  • GeurtsvanKessel CH, Bergen IM, Muskens F, et al. Both conventional and interferon killer dendritic cells have antigen-presenting capacity during influenza virus infection. PloS one 2009;4(9):e7187. [IF 5.7]
  • GeurtsvanKessel CH, Willart MA, Bergen IM, et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. The Journal of experimental medicine 2009;206(11):2339-49. [IF 15.6]
  • Haagmans BL, Andeweg AC, Osterhaus AD. The application of genomics to emerging zoonotic viral diseases. PLoS pathogens 2009;5(10):e1000557. [IF 9.1]
  • Hahne S, Donker T, Meijer A, et al. Epidemiology and control of influenza A(H1N1)v in the Netherlands: the first 115 cases. Euro Surveill 2009;14(27). [IF will be determined in 2011]
  • Holvast A, Stegeman CA, Benne CA, et al. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Annals of the rheumatic diseases 2009;68(6):873-8. [IF 7.1]
  • Holvast A, van Assen S, de Haan A, et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis and rheumatism 2009;60(8):2438-47. [IF 6.8]
  • Holvast A, van Assen S, de Haan A, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology (Oxford, England) 2009;48(10):1294-9. [IF  4.1]
  • Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD. Vaccine-induced enhancement of viral infections. Vaccine 2009;27(4):505-12. [IF 3.3]
  • Koopmans MP, Meijer A, van der Lubben MI, et al. [Combating the new influenza A (H1N1) virus. I. Overview of the relevant virological aspects]. Nederlands tijdschrift voor geneeskunde 2009;153:A770. [no IF]
  • Kreijtz JH, Bodewes R, van den Brand JM, et al. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 2009;27(36):4983-9. [IF 3.3]
  • Kreijtz JH, Osterhaus AD, Rimmelzwaan GF. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Human vaccines 2009;5(3):126-35. [IF 1.5]
  • Kreijtz JH, Suezer Y, de Mutsert G, et al. MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PloS one 2009;4(11):e7790. [IF 5.7]
  • Kreijtz JH, Suezer Y, de Mutsert G, et al. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 2009;27(45):6296-9. [IF 3.3]
  • Kreijtz JH, Suezer Y, de Mutsert G, et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. The Journal of infectious diseases 2009;199(3):405-13. [IF 5.7]
  • Latorre-Margalef N, Gunnarsson G, Munster VJ, et al. Effects of influenza A virus infection on migrating mallard ducks. Proceedings 2009;276(1659):1029-36. [IF 4.2]
  • Meijer A, Beerens A, Claas E, et al. Preparing the outbreak assistance laboratory network in the Netherlands for the detection of the influenza virus A(H1N1) variant. J Clin Virol 2009;45(3):179-84. [IF 3.3]
  • Munster VJ, Baas C, Lexmond P, et al. Practical considerations for high-throughput influenza A virus surveillance studies of wild birds by use of molecular diagnostic tests. Journal of clinical microbiology 2009;47(3):666-73. [IF 3.9]
  • Munster VJ, de Wit E, van den Brand JM, et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science (New York, NY 2009;325(5939):481-3. [IF 28.1]
  • Nauta JJ, Beyer WE, Osterhaus AD. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals 2009;37(4):216-21. [IF 1.1]
  • Osterhaus AD, Vanlangendonck C. Stakeholder dialogue, broadening of support and use of communication: an integrated and integral part of influenza preparedness. Vaccine 2009;27(45):6390-1. [IF 3.3]
  • Pike-Overzet K, de Ridder D, Schonewille T, Staal FJ. DNA microarray studies of hematopoietic subpopulations. Methods in molecular biology (Clifton, NJ 2009;506:403-21. [IF unknown]
  • Rappuoli R, Del Giudice G, Nabel GJ, et al. Public health. Rethinking influenza. Science (New York, NY 2009;326(5949):50. [IF 28.1]
  • Reemers SS, Groot Koerkamp MJ, Holstege FC, van Eden W, Vervelde L. Cellular host transcriptional responses to influenza A virus in chicken tracheal organ cultures differ from responses in in vivo infected trachea. Veterinary immunology and immunopathology 2009;132(2-4):91-100. [IF 1.9]
  • Reemers SS, van Haarlem DA, Groot Koerkamp MJ, Vervelde L. Differential gene-expression and host-response profiles against avian influenza virus within the chicken lung due to anatomy and airflow. The Journal of general virology 2009;90(Pt 9):2134-46. [IF 3.1]
  • Rimmelzwaan GF, Kreijtz JH, Bodewes R, Fouchier RA, Osterhaus AD. Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 2009;27(45):6363-5. [IF 3.3]
  • Rockx B, Baas T, Zornetzer GA, et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. Journal of virology 2009;83(14):7062-74. [IF 5.3]
  • Scharpe J, Peetermans WE, Vanwalleghem J, et al. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis 2009;54(1):77-85. [IF 4.8]
  • van Haarlem DA, van Kooten PJ, Rothwell L, Kaiser P, Vervelde L. Characterisation and expression analysis of the chicken interleukin-7 receptor alpha chain. Developmental and comparative immunology 2009;33(9):1018-26. [IF 2.8]
  • van Riel D, van den Brand JM, Munster VJ, et al. Pathology and virus distribution in chickens naturally infected with highly pathogenic avian influenza A virus (H7N7) During the 2003 outbreak in The Netherlands. Veterinary pathology 2009;46(5):971-6. [IF 1.4]
  • Wilschut J. Influenza vaccines: the virosome concept. Immunology letters 2009;122(2):118-21. [IF 2.9]
  • Zijtregtop EA, Wilschut J, Koelma N, et al. Which factors are important in adults' uptake of a (pre)pandemic influenza vaccine? Vaccine 2009;28(1):207-27. [IF 3.3]



  
  
Vironovative Intervet Solvay Pharmaceuticals Erasmus MC University Medical Center Groningen Radboud University Nijmegen Medical Centre Utrecht University VIRGO